<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40844124</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Antidepressant Remission and Manic Switch in Bipolar Depression: A Propensity Score Analysis.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>235</EndPage><MedlinePgn>228-235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13822</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Antidepressants remain among the most widely used class of drugs in treating bipolar disorder, despite their minimal efficacy in randomized clinical trials and concern for association with manic episodes. This study sought to evaluate the outcomes of antidepressant treatment in bipolar depression in a large naturalistic cohort study, STEP-BD, in terms of symptomatic remission as well as emergence of mania, using a propensity score (PS) analysis to reduce indication bias.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Propensity scores were developed to estimate the probability of antidepressant exposure using multivariate logistic regression models; these scores were then used to match antidepressant-exposed and non-exposed individuals. Cox regression models were used to estimate hazard ratios for manic switch and time to remission, adjusted for these scores in the matched population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Total sample included 2166 individuals, of whom 1085 were exposed to AD and 1081 were unexposed to AD; mean follow-up duration was 182.5 (SD: 44.6) days (median&#x2009;=&#x2009;126, ICR: 87.4). Cox regression models for manic switch with antidepressant exposure versus non-exposure yielded an unadjusted hazard ratio (HR) of 0.93 (95% CI 0.67-1.14) and PS-adjusted HR of 0.77 (95% CI 0.51-1.08), neither of which was statistically significantly different from 1. Probability of symptomatic remission was also not significantly associated with antidepressant exposure, with unadjusted and PS-adjusted HR of 1.15 (95% CI 0.97-1.37) and 1.02 (95% CI 0.87-1.23), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">With PS adjustment, there was no evidence of increased likelihood of manic switch or achievement of symptomatic remission associated with antidepressant use in bipolar depression. Our results underscore the ongoing need to identify alternative strategies for effective treatment of bipolar depression.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>V&#xf6;hringer</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-2460-4680</Identifier><AffiliationInfo><Affiliation>Departamento de Psiquiatr&#xed;a y Salud Mental, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad Medicina Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Millennium Institute for Depression and Personality Research, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barroilhet</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-2016-3662</Identifier><AffiliationInfo><Affiliation>Departamento de Psiquiatr&#xed;a y Salud Mental, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad Medicina Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>B&#xe1;rbara A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0009-0003-9405-0243</Identifier><AffiliationInfo><Affiliation>Departamento de Psiquiatr&#xed;a y Salud Mental, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad Medicina Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0002-5862-6757</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Quantitative Health, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH080001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="Y">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087122" MajorTopicYN="Y">Mania</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antidepressants</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">manic switch</Keyword><Keyword MajorTopicYN="N">pseudorandomized</Keyword></KeywordList><CoiStatement>Dr. Perlis receives salary support from JAMA + AI for service as Editor in Chief, and from JAMA-Network-Open for service as AI Editor. He has served on advisory boards or provided consulting to Circular Genomics, Genomind and Alkermes. He holds equity in Circular Genomics and Psy Therapeutics. He reports research support from the National Institute of Mental Health. The other authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844124</ArticleId><ArticleId IdType="mid">NIHMS2082920</ArticleId><ArticleId IdType="pmc">PMC12374073</ArticleId><ArticleId IdType="doi">10.1111/acps.13822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baldessarini RJ et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 58, 85&#x2013;91 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17215417</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin FK &amp; Jamison KR Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. (Oxford University Press, 2007).</Citation></Reference><Reference><Citation>Sachs GS et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53, 1028&#x2013;1042 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemi SN, Hsu DJ, Soldani F &amp; Goodwin FK Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 5, 421&#x2013;433 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14636365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemi SN, Lenox MS &amp; Baldessarini RJ Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 62, 565&#x2013;569 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11488370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemi SN et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71, 372&#x2013;380 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20409444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacchiarotti I et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170, 1249&#x2013;1262 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091043</ArticleId><ArticleId IdType="pubmed">24030475</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihmer Z &amp; Gonda X Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: the role of underlying bipolarity. Depress Res Treat 2011, 906462 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096313</ArticleId><ArticleId IdType="pubmed">21603142</ArticleId></ArticleIdList></Reference><Reference><Citation>Post RM et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders 3, 259&#x2013;265 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11912569</ArticleId></ArticleIdList></Reference><Reference><Citation>Post RM et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189, 124&#x2013;131 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16880481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijsman HJ, Geddes JR, Rendell JM, Nolen WA &amp; Goodwin GM Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161, 1537&#x2013;1547 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15337640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs GS et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356, 1711&#x2013;1722 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Viktorin A et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 171, 1067&#x2013;1073 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24935197</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefsen OH, Rohde C &amp; &#xd8;stergaard SD Revisiting the association between treatment with antidepressants and mania: A nationwide within-individual study of 3554 patients with bipolar disorder. Bipolar Disorders 25, 583&#x2013;591 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37308316</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde C, &#xd8;stergaard SD &amp; Jefsen OH A Nationwide Target Trial Emulation Assessing the Risk of Antidepressant-Induced Mania Among Patients With Bipolar Depression. Am J Psychiatry 181, 630&#x2013;638 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38946271</ArticleId></ArticleIdList></Reference><Reference><Citation>McGirr A, V&#xf6;hringer PA, Ghaemi SN, Lam RW &amp; Yatham LN Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 3, 1138&#x2013;1146 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28100425</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 46, 399&#x2013;424 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR &amp; Rubin DB The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41&#x2013;55 (1983).</Citation></Reference><Reference><Citation>Tohen M et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 11, 453&#x2013;473 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19624385</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 163, 217&#x2013;224 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs GS, Guille C &amp; McMurrich SL A clinical monitoring form for mood disorders. Bipolar Disorders 4, 323&#x2013;327 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12479665</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahabreh IJ et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 33, 1893&#x2013;1901 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409422</ArticleId><ArticleId IdType="pubmed">22711757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurth T et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163, 262&#x2013;270 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16371515</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 35, 2545&#x2013;2552 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055576</ArticleId><ArticleId IdType="pubmed">20827274</ArticleId></ArticleIdList></Reference><Reference><Citation>Stata Statistical Software: Release 12. StataCorp, LP; (2011).</Citation></Reference><Reference><Citation>Ghaemi S Treatment for Bipolar Depression: Acute &amp; Prophylactic Efficacy With Citalopram. (2017).</Citation></Reference><Reference><Citation>Yatham LN et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 208, 78&#x2013;86 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25999335</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler LL et al. Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. Am J Psychiatry 174, 266&#x2013;276 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28135846</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B et al. Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials. J Affect Disord 223, 41&#x2013;48 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28715727</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 76, 40&#x2013;46 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17170562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>